share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5:募资说明书
美股SEC公告 ·  09/25 17:25

Moomoo AI 已提取核心信息

BioVie has issued a supplement to its prospectus, effectively suspending the continuous offering of its Class A common stock under a previously established Sales Agreement with Cantor Fitzgerald & Co. as of September 25, 2024. The supplement amends information from the original prospectus supplement dated January 19, 2024, and the prospectus dated August 28, 2023. Since the initial offering, BioVie has sold $6,446 worth of shares. The company's common stock, which is traded on the Nasdaq under the symbol BIVI, had a last reported sale price of $1.18 per share on September 24, 2024. The Sales Agreement remains effective, but no further sales will occur until a new prospectus supplement is filed with the Securities and Exchange Commission.
BioVie has issued a supplement to its prospectus, effectively suspending the continuous offering of its Class A common stock under a previously established Sales Agreement with Cantor Fitzgerald & Co. as of September 25, 2024. The supplement amends information from the original prospectus supplement dated January 19, 2024, and the prospectus dated August 28, 2023. Since the initial offering, BioVie has sold $6,446 worth of shares. The company's common stock, which is traded on the Nasdaq under the symbol BIVI, had a last reported sale price of $1.18 per share on September 24, 2024. The Sales Agreement remains effective, but no further sales will occur until a new prospectus supplement is filed with the Securities and Exchange Commission.
biovie已发布了补充招股说明书,有效地暂停了根据先前与康弗兹杰拉德有限公司建立的销售协议在2024年9月25日之前继续提供其A类普通股。该补充文件修订了自2024年1月19日起日期的原始招股说明书补充和自2023年8月28日起日期的招股说明书中的信息。自首次发行以来,biovie已售出6446美元的股份。该公司的普通股在纳斯达克交易所以标的BIVI进行交易,截至2024年9月24日,最近的报价为每股1.18美元。销售协议仍然有效,但在提交新的招股说明书补充给美国证券交易委员会之前不会再进行进一步的销售。
biovie已发布了补充招股说明书,有效地暂停了根据先前与康弗兹杰拉德有限公司建立的销售协议在2024年9月25日之前继续提供其A类普通股。该补充文件修订了自2024年1月19日起日期的原始招股说明书补充和自2023年8月28日起日期的招股说明书中的信息。自首次发行以来,biovie已售出6446美元的股份。该公司的普通股在纳斯达克交易所以标的BIVI进行交易,截至2024年9月24日,最近的报价为每股1.18美元。销售协议仍然有效,但在提交新的招股说明书补充给美国证券交易委员会之前不会再进行进一步的销售。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息